home / stock / hrtx / hrtx news


HRTX News and Press, Heron Therapeutics Inc. From 11/13/19

Stock Information

Company Name: Heron Therapeutics Inc.
Stock Symbol: HRTX
Market: NASDAQ
Website: herontx.com

Menu

HRTX HRTX Quote HRTX Short HRTX News HRTX Articles HRTX Message Board
Get HRTX Alerts

News, Short Squeeze, Breakout and More Instantly...

HRTX - Heron Therapeutics to Present at the Stifel 2019 Healthcare Conference

SAN DIEGO , Nov. 13, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Bar...

HRTX - Heron Therapeutics EPS beats by $0.15, beats on revenue

Heron Therapeutics (NASDAQ: HRTX ): Q3 GAAP EPS of -$0.42 beats by $0.15 . More news on: Heron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

HRTX - Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Updates

SAN DIEGO , Nov. 12, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced fin...

HRTX - FDA accepts Heron's refiled HTX-011 application; shares up 6% premarket

The FDA accepts for review Heron Therapeutics' (NASDAQ: HRTX ) resubmitted marketing application seeking approval of HTX-011 for the management of postoperative pain. The agency's action date is March 26, 2020. More news on: Heron Therapeutics, Inc., Healthcare stocks news, Stocks on the...

HRTX - Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain

SAN DIEGO , Oct. 28, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announce...

HRTX - Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)

SAN DIEGO , Oct. 22, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced tha...

HRTX - 2 Stocks That Could Double Your Money in 2020

Buying growth stocks in an election year is generally ill-advised. During the last presidential election cycle in 2016, growth stocks, on balance, dramatically underperformed the broader markets, whereas value stocks as a whole produced market-beating returns on capital. Going one step further,&...

HRTX - Daily Insider Ratings Round Up 10/7/19

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

HRTX - Notable Insider Buying In 3 Equities

We cannot negotiate with people who say what's mine is mine and what's yours is negotiable ." - John F. Kennedy Stocks trading slightly down across the board yesterday in the first trading day of the week. Chinese/American trade talks remain a key 'watch item' for investors this week. Hig...

HRTX - Why HP, Heron Therapeutics, and Avnet Slumped Today

Major benchmarks generally did well on Friday, as investors were pleased to get good news on the employment front to help counter some of the weaker readings in economic data in recent days. After such a significant pullback in stocks, many market participants also seemed ready to have at least ...

Previous 10 Next 10